Weight Loss Injections Singapore: Do They Protect Your Heart?

Weight-loss injections are usually discussed in terms of kilograms lost, appetite reduction and changes in body shape. However, their potential effects go beyond the weighing scale.

Some of these medications can improve blood pressure, blood sugar, cholesterol, inflammation and other factors associated with cardiovascular disease. More importantly, one specific weight-loss injection has now been shown to reduce the risk of heart attack, stroke and cardiovascular death in a carefully defined group of high-risk patients.

In Singapore, the weight-management form of semaglutide was approved for cardiovascular risk reduction in August 2025. The indication applies to adults with established cardiovascular disease who also have overweight or obesity. This does not mean every person taking a weight-loss injection receives the same heart protection, or that all injectable weight-management medications are interchangeable.

The most accurate answer is therefore:

Yes, certain weight-loss injections can protect the heart in certain patients — but the evidence depends on the medication, the person's existing health conditions and the outcome being measured.

Weight Loss Injections Singapore: The Key Facts at a Glance

Why Excess Weight Affects the Heart

Excess body fat is not simply stored energy. Fat tissue, particularly around the abdomen and internal organs, can influence hormones, inflammation, insulin sensitivity and blood-vessel function.

Over time, obesity can increase the likelihood of:

• High blood pressure

• Type 2 diabetes

• Abnormal cholesterol levels

• Obstructive sleep apnoea

• Fatty liver disease

• Chronic kidney disease

• Coronary artery disease

• Stroke

• Atrial fibrillation

• Heart failure

These risks do not depend on body weight alone. A person's age, smoking history, family history, blood pressure, cholesterol, blood sugar and existing cardiovascular disease also matter.

This is why doctors assessing weight loss injections in Singapore should consider overall metabolic and cardiovascular health, rather than looking only at BMI or a desired target weight.

What Are GLP-1 Weight-Loss Injections?

Several modern weight-management injections work through hormones involved in appetite, digestion and blood sugar regulation.

GLP-1 receptor agonists

GLP-1 is a hormone naturally released after eating. Medications that mimic GLP-1 can:

• Reduce hunger and food cravings

• Increase fullness after eating

• Slow the movement of food through the stomach

• Support insulin release when blood sugar is elevated

• Reduce glucagon, a hormone that raises blood sugar

Semaglutide and liraglutide are examples of GLP-1 receptor agonists.

Dual GIP and GLP-1 receptor agonists

Tirzepatide acts on both GIP and GLP-1 receptors. It can produce substantial weight loss and improvements in blood sugar, but its cardiovascular evidence must still be interpreted according to the specific population and trial involved. In Singapore, tirzepatide was approved in June 2025 for type 2 diabetes and for weight management in adults with obesity, or overweight with at least one related medical condition.

Weight Loss Injections and Heart Health: What Did the SELECT Trial Find?

The most important study answering this question is the SELECT trial.

SELECT involved more than 17,600 adults aged 45 years or older.

Participants had a BMI of at least 27 kg/m², established cardiovascular disease, and no diabetes. They received either once-weekly semaglutide 2.4 mg or a placebo. Both groups continued to receive standard cardiovascular care, including treatment of blood pressure and cholesterol where appropriate.

Major cardiovascular events occurred in:

• 6.5% of participants receiving semaglutide

• 8.0% of participants receiving placebo

This represented a 20% relative reduction in the combined risk of cardiovascular death, non-fatal heart attack or non-fatal stroke. The absolute difference between the two groups was 1.5 percentage points over the study period.

The result was important because earlier cardiovascular trials of GLP-1 medications had mainly involved people with type 2 diabetes. SELECT showed that semaglutide could reduce cardiovascular events even in people without diabetes, provided they already had cardiovascular disease and overweight or obesity.

What "20% lower risk" actually means

A 20% relative reduction does not mean that 20 out of every 100 patients will avoid a heart attack. In SELECT, 8.0% of the placebo group experienced a major cardiovascular event compared with 6.5% of the semaglutide group.

The difference was meaningful, but the benefit was concentrated within a group that already had substantial cardiovascular risk. Patients should look at both relative and absolute risk when discussing treatment benefits with a doctor.

The Most Important Limitation: SELECT Was Not a General Weight-Loss Trial

The SELECT participants were not healthy adults trying to lose a few kilograms for appearance or general wellness. They had established cardiovascular disease, such as a previous heart attack, stroke or symptomatic peripheral artery disease.

The trial therefore provides evidence for secondary prevention — preventing another cardiovascular event in someone who already has cardiovascular disease.

It does not prove that semaglutide prevents a first heart attack in every person with overweight, nor does it establish cardiovascular protection in younger, low-risk individuals using medication primarily for cosmetic weight loss. This distinction is essential when discussing weight loss injections and heart health.

Singapore Approval for Semaglutide and Heart Protection

The US Food and Drug Administration approved the weight-management semaglutide product for cardiovascular risk reduction in March 2024. In Singapore, the additional indication was approved on 22 August 2025.

In Singapore, this product is indicated alongside a reduced-calorie diet and increased physical activity to reduce major cardiovascular events in adults who have both established cardiovascular disease and either overweight or obesity.

This makes the weight-management semaglutide product the weight-management injection with the clearest direct evidence and local indication for reducing major cardiovascular events in this specific population.

Do the Different Semaglutide Products Offer the Same Heart Protection?

Semaglutide is sold as more than one product, and these should not be treated as interchangeable.

The diabetes product

The diabetes form of semaglutide is primarily used for adults with type 2 diabetes. It can lower the likelihood of heart attack, stroke and death in patients with type 2 diabetes and known heart disease.

The weight-management product

The weight-management form of semaglutide is registered for chronic weight management and, in eligible adults, reducing major cardiovascular events. The cardiovascular indication for adults without diabetes was based on the 2.4 mg semaglutide regimen studied in SELECT.

A patient should therefore not assume that using any dose of semaglutide under any product automatically reproduces the SELECT results. The product, indication, patient group and treatment plan matter.

Which Weight Loss Injections in Singapore Have Proven Heart Benefits?

Several GLP-1 receptor agonists have reduced cardiovascular events in large diabetes trials. A 2024 meta-analysis found that GLP-1 receptor agonists reduced major cardiovascular events by approximately 13% among trial participants with type 2 diabetes. However, differences between drugs, doses, populations and approved indications remain important.

Does Tirzepatide Protect the Heart?

Tirzepatide is a dual GIP and GLP-1 receptor agonist. It is approved in Singapore for type 2 diabetes and weight management, but its current indication does not broadly state that it reduces heart attacks and strokes in adults with obesity. Two areas of evidence are relevant.

Cardiovascular outcomes in type 2 diabetes

The SURPASS-CVOT trial compared tirzepatide with dulaglutide in people with type 2 diabetes and established atherosclerotic cardiovascular disease. Tirzepatide was found to be non-inferior to dulaglutide for cardiovascular death, heart attack or stroke. In simple terms, it did not result in a higher cardiovascular risk than a GLP-1 medication already known to have cardiovascular benefits.

However, this was an active-comparator trial rather than a placebo-controlled trial like SELECT. Non-inferiority to dulaglutide is not the same as proving that tirzepatide reduces major cardiovascular events in all adults taking it for weight loss.

Obesity-related heart failure

Tirzepatide has also shown meaningful benefits in patients with obesity and heart failure with preserved ejection fraction, commonly shortened to HFpEF. In the SUMMIT trial, cardiovascular death or worsening heart failure occurred in:

• 9.9% of patients receiving tirzepatide

• 15.3% of patients receiving placebo

The reduction was mainly driven by fewer worsening heart-failure events. Cardiovascular deaths alone were uncommon, and the trial was not large enough to establish a separate mortality benefit with certainty. Patients receiving tirzepatide also reported better symptoms and health status. This is encouraging evidence, but it applies specifically to people with obesity-related HFpEF — not every person using tirzepatide for weight loss.

Can Weight-Loss Injections Help People With Heart Failure?

Obesity is an important contributor to HFpEF, a form of heart failure in which the heart's pumping percentage may appear normal but the heart remains stiff and does not fill efficiently. Patients may experience breathlessness, reduced exercise tolerance, leg swelling, fatigue and difficulty performing everyday activities.

Trials involving semaglutide found improvements in heart-failure symptoms, physical limitations, exercise capacity and weight among people with obesity-related HFpEF. Similar findings have been reported with tirzepatide, together with a reduction in worsening heart-failure events.

These injections are not substitutes for standard heart-failure medication. Treatment must be coordinated with the patient's cardiologist or regular doctor, especially when diuretics, blood pressure medicines or diabetes medicines are being used.

How Might Weight-Loss Injections Protect the Heart?

Researchers are still determining how much of the cardiovascular benefit comes directly from weight loss and how much comes from other effects. Several mechanisms are likely involved.

1. Lower body weight

Losing excess weight reduces the workload placed on the heart and may improve mobility, sleep apnoea, insulin sensitivity and physical activity.

2. Better blood pressure

GLP-1-based treatments often produce modest improvements in systolic blood pressure. Even a moderate long-term reduction in blood pressure can contribute to lower cardiovascular risk.

3. Improved glucose control

For patients with diabetes or prediabetes, better glucose control can reduce metabolic stress and may slow the progression of vascular and kidney complications.

4. Changes in cholesterol and triglycerides

Weight reduction and improved insulin sensitivity may lower triglycerides and improve other aspects of the lipid profile.

5. Reduced inflammation

Obesity is associated with chronic low-grade inflammation. GLP-1-based treatments may reduce inflammatory markers, although it remains difficult to separate direct medication effects from the effects of weight loss.

6. Kidney protection

The heart and kidneys are closely connected. Clinical-trial meta-analyses have found reductions in important kidney outcomes as well as cardiovascular events with GLP-1 receptor agonists.

7. Possible direct effects on blood vessels and plaque

Laboratory and clinical research suggests that GLP-1 receptor signalling may affect blood-vessel function and atherosclerotic inflammation. However, these mechanisms should not be overstated as proven direct effects in every patient.

Does Greater Weight Loss Automatically Mean Greater Heart Protection?

Not necessarily. A medication that produces more weight loss is not automatically proven to prevent more heart attacks or strokes.

Cardiovascular protection must be demonstrated through outcome trials that follow patients long enough to record actual clinical events.

A weight-loss study may measure percentage of weight lost, waist circumference, blood pressure, blood sugar, cholesterol and liver fat. A cardiovascular outcome trial measures events such as cardiovascular death, non-fatal heart attack, non-fatal stroke and heart-failure hospitalisation.

These are not interchangeable outcomes.

Tirzepatide may produce greater average weight loss than semaglutide in head-to-head obesity studies, but the weight-management semaglutide product currently has the clearest direct placebo-controlled evidence for reducing major cardiovascular events in adults with established cardiovascular disease and overweight or obesity.

Who Is Most Likely to Receive Cardiovascular Benefit?

The evidence is strongest for patients who have a high underlying risk. This may include adults with:

• A previous heart attack

• A previous stroke

• Peripheral artery disease

• Established coronary artery disease

• Type 2 diabetes and cardiovascular disease

• Type 2 diabetes and chronic kidney disease

• Obesity-related HFpEF

• Obesity together with several cardiovascular risk factors

For someone who already has cardiovascular disease, even a modest relative reduction in risk may be meaningful because their starting risk is high.

For a younger person without diabetes, high blood pressure, high cholesterol or known cardiovascular disease, the absolute cardiovascular benefit is likely to be much smaller and has not been established to the same degree.

Who Should Not View These Injections as Heart Medication?

Weight-loss injections should not be viewed as routine heart-protection injections for everyone. The evidence does not support using them solely for cardiovascular prevention in:

• People of normal weight

• Individuals seeking only a small cosmetic weight reduction

• People with no meaningful metabolic or cardiovascular risk

• Patients who have not been medically assessed

• Adolescents using injections without appropriate specialist supervision

• Anyone obtaining an injectable product from an unregulated source

The decision should be based on approved indications, expected medical benefit, potential adverse effects and the patient's overall treatment plan.

Weight Loss Injections Do Not Replace Standard Heart Treatment

In SELECT, patients continued to receive standard medical care. Semaglutide was added to — not substituted for — appropriate cardiovascular treatment. Depending on the patient, standard prevention may still include statins or other cholesterol-lowering treatment, blood pressure medication, antiplatelet medication, diabetes treatment, smoking cessation, physical activity, dietary changes, management of sleep apnoea and regular cardiovascular follow-up.

Stopping these treatments because weight or blood sugar has improved could increase cardiovascular risk. Medication changes should be made only after discussing them with the prescribing doctor.

What Are the Risks and Side Effects?

The most common adverse effects are gastrointestinal and may be more noticeable when treatment is started or adjusted. They include nausea, vomiting, diarrhoea, constipation, abdominal discomfort, bloating or belching, acid reflux, reduced appetite and fatigue.

Important but less common concerns include gallbladder disease, pancreatitis, dehydration-related kidney problems, severe allergic reactions and worsening diabetic eye disease in some patients whose glucose improves rapidly.

Semaglutide should not be used in patients with certain thyroid-cancer histories, including a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Pregnancy, plans for pregnancy, breastfeeding, previous pancreatitis, kidney disease, liver disease and significant digestive disorders should be discussed before treatment.

Low blood sugar is not usually expected when these medications are used alone in a person without diabetes. The risk increases when they are combined with insulin or medications that stimulate insulin release. Our guide to managing weight-loss injection side effects covers this in more detail.

What Should a Doctor Check Before Prescribing?

A proper consultation for weight loss injections in Singapore should involve more than recording height and weight. Assessment may include BMI and waist circumference, blood pressure, fasting glucose or HbA1c, cholesterol and triglycerides, kidney and liver function, current medications and supplements, previous heart attack, stroke or heart failure, family history of cardiovascular disease, gallbladder or pancreatic history, thyroid-cancer history, digestive symptoms, pregnancy plans, eating patterns and physical activity, previous weight-loss attempts, and realistic goals with a long-term maintenance plan.

For patients with known heart disease, communication between the primary-care doctor, cardiologist and other treating specialists may be appropriate.

What Should Be Monitored During Treatment?

Monitoring should look beyond the amount of weight lost. Useful measures may include weight and waist circumference, blood pressure, heart rate, blood sugar in patients with diabetes, kidney function where clinically indicated, tolerance of food and fluids, gastrointestinal side effects, symptoms of dizziness or dehydration, changes in diabetes or blood pressure medication needs, and maintenance of muscle mass and adequate nutrition.

Rapid weight loss without sufficient protein intake and resistance exercise can contribute to loss of lean tissue. The aim should be improved health and function — not simply the lowest possible number on the scale.

What Happens When the Injection Is Stopped?

Obesity is generally a chronic condition. Appetite can increase again after medication is stopped, and weight regain is common if no long-term strategy is in place. Any improvements in blood pressure, glucose or cholesterol may also lessen if substantial weight is regained. We explain this in detail in our guide to what happens when you stop tirzepatide.

Patients should discuss how long treatment may be needed, what would justify continuing or stopping, side-effect management, costs and sustainability, nutrition and exercise support, a maintenance plan, and how cardiovascular risk factors will continue to be treated. The potential heart benefit should therefore be viewed as part of sustained medical management rather than a short course before a holiday, wedding or event.

Weight Loss Injections Singapore: Questions to Ask Your Doctor

Before starting treatment, consider asking:

1. Do I meet the medical criteria for treatment?

2. Am I being treated primarily for weight management, diabetes or cardiovascular risk?

3. Do I already have cardiovascular disease?

4. Which medication has evidence for someone with my medical profile?

5. What benefits are realistic for me?

6. What side effects should I report?

7. Could my blood pressure or diabetes medicines require adjustment?

8. How will we protect muscle mass and nutrition?

9. How often will my progress be reviewed?

10. What is the long-term plan if the medication works?

Frequently Asked Questions

Do weight-loss injections prevent heart attacks?

The weight-management form of semaglutide has been shown to reduce the combined risk of cardiovascular death, non-fatal heart attack and non-fatal stroke in adults with established cardiovascular disease and overweight or obesity. This result should not be generalised to every injection or every patient.

Can I use a weight-loss injection instead of taking a statin?

No. These injections do not replace cholesterol-lowering medication. Participants in the major cardiovascular trial continued standard cardiovascular care.

Is the diabetes form of semaglutide approved for weight loss?

The diabetes product is primarily a diabetes medication. A separate, higher-dose semaglutide product is registered specifically for weight management. Patients should use the product prescribed for their medical indication.

Is tirzepatide better for the heart because it can produce more weight loss?

That conclusion cannot be made from weight loss alone. Tirzepatide has encouraging cardiovascular and heart-failure evidence, but a medication's effect on clinical events must be established in dedicated outcome trials.

Can someone without diabetes receive heart benefits?

Yes, but the strongest evidence is from adults without diabetes who already had cardiovascular disease and had overweight or obesity.

Will losing weight naturally also protect the heart?

Sustained weight reduction through nutrition, activity, sleep and behavioural changes can improve several cardiovascular risk factors. Medication is one possible tool and should be combined with broader lifestyle and medical management.

Are weight-loss injections suitable for teenagers?

Some products have specific adolescent indications, but treatment requires careful medical assessment. It should not be used casually or obtained without appropriate clinical supervision.

The Bottom Line

So, do weight-loss injections protect your heart? Certain ones can — but only in clearly studied patient groups.

The strongest evidence currently applies to the weight-management form of semaglutide in adults with established cardiovascular disease and overweight or obesity. In this population, semaglutide reduced the combined risk of cardiovascular death, heart attack and stroke when added to standard medical care.

Other GLP-1-based medications have demonstrated cardiovascular benefits in people with type 2 diabetes, while tirzepatide has shown promising results in obesity-related heart failure and cardiovascular safety studies. However, patients should not assume that every medication, dose or product provides identical protection.

For patients considering weight loss injections in Singapore, the decision should be based on more than how many kilograms might be lost. A doctor should assess cardiovascular history, diabetes risk, blood pressure, cholesterol, kidney health, medication safety and the likelihood of meaningful long-term benefit. Weight-loss treatment is most valuable when it improves not only body weight, but also health, mobility, metabolic control and future cardiovascular risk.

Considering Weight-Loss Treatment in Singapore?

A medical weight-management consultation can help determine whether injectable treatment is appropriate for your BMI, health conditions and long-term goals. At Nee Soon Clinic, assessment may include weight history, blood pressure, glucose and cholesterol risk, existing medical conditions, medication suitability and a personalised follow-up plan.

You can read more about our medical weight-loss programme. Weight-loss injections are prescription medications and should be used under medical supervision. Results and suitability vary between individuals.

References

1. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 2023.

2. US Food and Drug Administration. Approval of a semaglutide weight-management product for cardiovascular risk reduction, March 2024.

3. Nicholls SJ, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (SURPASS-CVOT).

4. Packer M, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT). New England Journal of Medicine.

5. Kosiborod MN, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF).

6. Badve SV, et al. Effects of GLP-1 Receptor Agonists on Kidney and Cardiovascular Outcomes: Meta-analysis of Randomised Trials.

7. Official information: https://www.wegovy.com/ and https://mounjaro.lilly.com/ and https://www.ozempic.com/

Disclaimer: The information provided in this article is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. The content is not intended to be a comprehensive source of information and should not be relied upon as such. Reliance on any information provided in this article is solely at your own risk. The authors and the publisher do not endorse or recommend any specific tests, physicians, products, procedures, opinions, or other information that may be mentioned in the article. Any reliance on the information in this article is solely at the reader's own risk.